Efficacy of Biologic Therapy in Moderate-to-Severe Psoriasis
Key Findings
Biologic therapy demonstrated 89% reduction in PASI score at week 16 compared to 12% with placebo. Quality of life improved significantly with minimal adverse events.
Summary
Biologic therapy demonstrated 89% reduction in PASI score at week 16 compared to 12% with placebo. Quality of life improved significantly with minimal adverse events.
Study Design
Phase 3, randomized, double-blind, placebo-controlled trial in 450 patients with moderate-to-severe plaque psoriasis.
Methods
Patients received subcutaneous injections at weeks 0, 4, and every 12 weeks thereafter. Primary endpoint was PASI 75 response at week 16.
Results
PASI 75 achieved in 89% vs 12% (p<0.001). PASI 90 in 72% vs 4%. Adverse events comparable to placebo.
Conclusions
Biologic therapy provides rapid, sustained improvement in moderate-to-severe psoriasis with excellent safety profile.
Full Abstract
This study examined efficacy of biologic therapy in moderate-to-severe psoriasis in a comprehensive clinical investigation.